Tao Shao-Hong, Lei Yu-Qing, Tan Yi-Mei, Yang Yu-Bo, Xie Wei-Ning
Affiliated Guangdong Hospital of Integrated Traditional Chinese and Western Medicine of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
School of Traditional Chinese Medicine, Jinan University, Guangzhou, Guangdong, China.
Front Med (Lausanne). 2024 Oct 8;11:1476419. doi: 10.3389/fmed.2024.1476419. eCollection 2024.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, continues to rise with rapid economic development and poses significant challenges to human health. No effective drugs are clinically approved. MASLD is regarded as a multifaceted pathological process encompassing aberrant lipid metabolism, insulin resistance, inflammation, gut microbiota imbalance, apoptosis, fibrosis, and cirrhosis. In recent decades, herbal medicines have gained increasing attention as potential therapeutic agents for the prevention and treatment of MASLD, due to their good tolerance, high efficacy, and low toxicity. In this review, we summarize the pathological mechanisms of MASLD; emphasis is placed on the anti-MASLD mechanisms of Chinese herbal formula (CHF), especially their effects on improving lipid metabolism, inflammation, intestinal flora, and fibrosis. Our goal is to better understand the pharmacological mechanisms of CHF to inform research on the development of new drugs for the treatment of MASLD.
代谢功能障碍相关脂肪性肝病(MASLD),以前称为非酒精性脂肪性肝病,随着经济的快速发展,其发病率持续上升,对人类健康构成重大挑战。临床上尚无获批的有效药物。MASLD被认为是一个多方面的病理过程,包括异常的脂质代谢、胰岛素抵抗、炎症、肠道微生物群失衡、细胞凋亡、纤维化和肝硬化。近几十年来,草药因其耐受性好、疗效高、毒性低,作为预防和治疗MASLD的潜在治疗药物受到越来越多的关注。在这篇综述中,我们总结了MASLD的病理机制;重点阐述了中药复方(CHF)抗MASLD的机制,尤其是其在改善脂质代谢、炎症、肠道菌群和纤维化方面的作用。我们的目标是更好地理解CHF的药理机制,为开发治疗MASLD的新药提供研究依据。